National Institute for Occupational Safety and Health, Safety and Occupational Health Study Section, 30467 [05-10542]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 101 / Thursday, May 26, 2005 / Notices
the role of amplification; models of
early intervention; and the need for
future research.
Agenda items are subject to change as
priorities dictate.
FOR FURTHER INFORMATION CONTACT:
Marcus Gaffney, M.P.H., National
Center on Birth Defects and
Developmental Disabilities, CDC, 1600
Clifton Road, NE., M/S E–88, Atlanta,
Georgia 30333. Telephone: (404) 498–
3031.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Dated: May 20, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–10541 Filed 5–25–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
improvements in the delivery of occupational
safety and health services, and the
prevention of work-related injury and illness.
It is anticipated that research funded will
promote these program goals.
Matters to be Discussed: The meeting will
convene in open session from 8–8:15 a.m. on
June 21, 2005, to address matters related to
the conduct of Study Section business. The
remainder of the meeting will proceed in
closed session. The purpose of the closed
sessions is for the study section to consider
safety and occupational health-related grant
applications. These portions of the meeting
will be closed to the public in accordance
with provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and the
Determination of the Director, Management
Analysis and Services Office, Centers for
Disease Control and Prevention, pursuant to
Section 10(d) Pub. L. 92–463.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Price
Connor, Ph.D., NIOSH Health Scientist, 1600
Clifton Road, NE., Mailstop E–74, Atlanta,
Georgia 30333, telephone 404/498–2511, fax
404/498–2569.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 20, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–10542 Filed 5–25–05; 8:45 am]
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health, Safety and
Occupational Health Study Section
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting.
BILLING CODE 4163–18–P
Name: Safety and Occupational Health
Study Section (SOHSS), National Institute for
Occupational Safety and Health (NIOSH).
Times and Dates: 8 a.m.–5 p.m., June 21,
2005. 8 a.m.–5 p.m., June 22, 2005.
Place: Embassy Suites Hotel, 1900
Diagonal Road, Alexandria, Virginia, 22314,
telephone 703/684–5900, fax 703/684–1403.
Status: Open 8 a.m.–8:15 a.m., June 21,
2005. Closed 8:15 a.m.–5 p.m., June 21, 2005.
Closed 8 a.m.–5 p.m., June 22, 2005.
Purpose: The Safety and Occupational
Health Study Section will review, discuss,
and evaluate grant application(s) received in
response to the Institute’s standard grants
review and funding cycles pertaining to
research issues in occupational safety and
health, and allied areas.
It is the intent of NIOSH to support broadbased research endeavors in keeping with the
Institute’s program goals. This will lead to
improved understanding and appreciation for
the magnitude of the aggregate health burden
associated with occupational injuries and
illnesses, as well as to support more focused
research projects, which will lead to
[Docket No. 2005D–0169]
VerDate jul<14>2003
19:11 May 25, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Draft Guidance on Useful Written
Consumer Medication Information
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Useful Written Consumer Medication
Information (CMI).’’ CMI is written
information developed for consumers
about prescription drugs that is
distributed to consumers when they
have prescriptions filled. The guidance
discusses general issues and makes
recommendations on the content of
useful written CMI.
DATES: Submit written or electronic
comments on the draft guidance by July
25, 2005. General comments on agency
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
30467
guidance documents are welcome at any
time.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
FOR FURTHER INFORMATION CONTACT:
Ellen Tabak, Center for Drug Evaluation
and Research (HFD–410), Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
7843.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance entitled ‘‘Useful
Written Consumer Medication
Information (CMI).’’ This draft guidance
is intended to assist individuals or
organizations (e.g., pharmacies, private
vendors, healthcare associations) in
developing useful written CMI. CMI is
written information about prescription
drugs developed by organizations or
individuals, other than a drug’s
manufacturer, that is intended for
distribution to consumers at the time of
dispensing. Since neither FDA nor the
drug’s manufacturer reviews or
approves CMI, FDA recommends that
the developers of written medication
information use the factors discussed in
this guidance to ensure that their CMI
is useful to consumers.
Traditionally, FDA has believed that
when people are well-informed about
the medications they take, they are able
to make better decisions about their
healthcare and better use of the
prescription medications available to
them. Access to useful written
information about prescription
medications is important to ensuring
appropriate use of these products. In
1996, a steering committee comprised of
interested stakeholders (including
healthcare professionals, consumer
organizations, voluntary health
agencies, pharmaceutical
manufacturers, prescription drug
wholesalers, drug information database
companies, CMI developers, and
E:\FR\FM\26MYN1.SGM
26MYN1
]]>Agencies
[Federal Register Volume 70, Number 101 (Thursday, May 26, 2005)]
[Notices]
[Page 30467]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-10542]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health, Safety and
Occupational Health Study Section
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Name: Safety and Occupational Health Study Section (SOHSS),
National Institute for Occupational Safety and Health (NIOSH).
Times and Dates: 8 a.m.-5 p.m., June 21, 2005. 8 a.m.-5 p.m.,
June 22, 2005.
Place: Embassy Suites Hotel, 1900 Diagonal Road, Alexandria,
Virginia, 22314, telephone 703/684-5900, fax 703/684-1403.
Status: Open 8 a.m.-8:15 a.m., June 21, 2005. Closed 8:15 a.m.-5
p.m., June 21, 2005. Closed 8 a.m.-5 p.m., June 22, 2005.
Purpose: The Safety and Occupational Health Study Section will
review, discuss, and evaluate grant application(s) received in
response to the Institute's standard grants review and funding
cycles pertaining to research issues in occupational safety and
health, and allied areas.
It is the intent of NIOSH to support broad-based research
endeavors in keeping with the Institute's program goals. This will
lead to improved understanding and appreciation for the magnitude of
the aggregate health burden associated with occupational injuries
and illnesses, as well as to support more focused research projects,
which will lead to improvements in the delivery of occupational
safety and health services, and the prevention of work-related
injury and illness. It is anticipated that research funded will
promote these program goals.
Matters to be Discussed: The meeting will convene in open
session from 8-8:15 a.m. on June 21, 2005, to address matters
related to the conduct of Study Section business. The remainder of
the meeting will proceed in closed session. The purpose of the
closed sessions is for the study section to consider safety and
occupational health-related grant applications. These portions of
the meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and
Services Office, Centers for Disease Control and Prevention,
pursuant to Section 10(d) Pub. L. 92-463.
Agenda items are subject to change as priorities dictate.
For Further Information Contact: Price Connor, Ph.D., NIOSH
Health Scientist, 1600 Clifton Road, NE., Mailstop E-74, Atlanta,
Georgia 30333, telephone 404/498-2511, fax 404/498-2569.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: May 20, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-10542 Filed 5-25-05; 8:45 am]
BILLING CODE 4163-18-P
